US Patent 11179365 Pharmaceutical combination comprising LSZ102 and ribociclib
Patent 11179365 was granted and assigned to Novartis on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+392 characters)
Article
Patent abstract
The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111793650
Date of Patent
November 23, 2021
0Patent Application Number
161902980
Date Filed
November 14, 2018
0Official Website
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111793650
Date of Patent
November 23, 2021
0Patent Application Number
161902980
Date Filed
November 14, 2018
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 25 Nov, 2021
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11179365 Pharmaceutical combination comprising LSZ102 and ribociclib
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11179365
Date of patent
November 23, 2021
Patent application number
16190298
Date Filed
November 14, 2018
Patent primary examiner
Find more entities like US Patent 11179365 Pharmaceutical combination comprising LSZ102 and ribociclib
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
